1. Introduction {#sec1-ijms-21-04906}
===============

Hepatocellular carcinoma (HCC), one of the most common malignancies worldwide, is usually accompanied by advanced liver fibrosis or cirrhosis \[[@B1-ijms-21-04906],[@B2-ijms-21-04906]\]. The etiology of background liver diseases differs geographically, however, chronic viral hepatitis due to either hepatitis B virus (HBV) or hepatitis C virus (HCV) is the leading cause of HCC in many countries \[[@B3-ijms-21-04906],[@B4-ijms-21-04906],[@B5-ijms-21-04906]\]. Other major etiologies, such as alcoholic liver disease (ALD) and nonalcoholic steatohepatitis (NASH) have also been increasing \[[@B6-ijms-21-04906]\].

Liver fibrosis, which is a consequence of inflammation and regeneration, represents accumulated damage to DNA in hepatocytes. Indeed, liver fibrosis seems to be one of the risk factors for HCC development \[[@B7-ijms-21-04906]\]. Until recently, the staging of liver fibrosis could only be assessed with a liver biopsy. However, liver biopsy occasionally causes severe complications in up to 3% of patients, including death in 0.03% \[[@B8-ijms-21-04906]\]. There is, therefore, a need for an accurate noninvasive test for the diagnosis and staging of liver fibrosis.

Fibrosis is accompanied by an accumulation of extracellular matrix (ECM), following the activation of hepatic stellate cells (HSCs) and the production of transforming growth factor β1 (TGF-β1). We previously reported that simple stromal injury mimics liver fibrosis with HSC activation, fibronectin production, and collagen deposition using a mouse model \[[@B9-ijms-21-04906]\]. In a healthy liver, the turnover of ECM is regulated by enzymes called matrix metalloproteinase (MMPs) and their specific inhibitors, tissue inhibitors of metalloproteinases (TIMPs). The context of this review is demonstrated in [Figure 1](#ijms-21-04906-f001){ref-type="fig"}.

In this review, we summarize noninvasive fibrosis tests that have already been applied in daily clinical practice and review the molecular mechanism of liver fibrosis and some candidate molecular markers that are now being studied and are expected to be used in future clinical practice.

2. Noninvasive Imaging Techniques {#sec2-ijms-21-04906}
=================================

Elastography is a noninvasive imaging technique and is now widely accepted as a fibrosis assessment in clinical practice. Most methods measure the propagation speed of shear waves to estimate liver stiffness. There are ultrasound (US) elastography and magnetic resonance imaging (MRI) elastography. The diagnostic performance and characteristics of each technique are listed in [Table 1](#ijms-21-04906-t001){ref-type="table"} and [Table 2](#ijms-21-04906-t002){ref-type="table"}.

2.1. US Elastography {#sec2dot1-ijms-21-04906}
--------------------

### 2.1.1. Static Strain Imaging {#sec2dot1dot1-ijms-21-04906}

In static strain elastography, pressure is generated by mechanical or manual compression, and then the amount of target lesion deformation is measured \[[@B29-ijms-21-04906]\]. The applied compression is either manual by the transducer or physiological from the heartbeat or lung movements \[[@B16-ijms-21-04906]\]. The main clinical use of this technique is in the evaluation of surface organs such as breast and thyroid lesions \[[@B17-ijms-21-04906]\]. This technique could be potentially useful in evaluating large liver tumors: and for discriminating hard and soft tumors \[[@B18-ijms-21-04906]\].

### 2.1.2. One-Dimensional Transient Elastography {#sec2dot1dot2-ijms-21-04906}

Transient elastography is the first commercialized shear wave elastography (SWE) system. Transient elastography has a single measuring device that contains a vibrator and an ultrasound transducer \[[@B19-ijms-21-04906],[@B20-ijms-21-04906]\]. The new XL probe of Firboscan^®^ (Echosens, Paris, France) is now commercially available because of the frequent measurement failure of standard probes in obese patients \[[@B21-ijms-21-04906]\]. The diagnostic performance (sensitivity, specificity, cutoff values, area under the receiver operating characteristic curve \[AUROC\]), as reported in a meta-analysis, is demonstrated in [Table 1](#ijms-21-04906-t001){ref-type="table"} \[[@B10-ijms-21-04906],[@B11-ijms-21-04906]\]. Transient elastography is the most widely studied and accepted elastography method and it is reported to be useful in predicting clinical outcomes \[[@B22-ijms-21-04906],[@B23-ijms-21-04906],[@B24-ijms-21-04906],[@B25-ijms-21-04906]\]. The advantages of transient elastography are its wide range value (from 0 kilopascal \[kPa\] to 75 kPa) and rapid and straightforward use in outpatient clinics. The disadvantages of the technique are the requirement of a special apparatus, the lack of two-dimensional grey scale imaging B-mode and real-time liver stiffness imaging, and difficulty in the measurement of patients with obesity, ascites, or narrow intercostal space.

### 2.1.3. Point SWE {#sec2dot1dot3-ijms-21-04906}

Point SWE uses an acoustic radiation force impulse (ARFI) to generate shear waves in the liver. The examiner is able to use grayscale ultrasound imaging to locate a small region of interest (ROI) in the right hepatic lobe, avoiding large vessels and the gallbladder. The diagnostic performance of SWE, as reported in a meta-analysis, is demonstrated in [Table 1](#ijms-21-04906-t001){ref-type="table"} \[[@B12-ijms-21-04906],[@B13-ijms-21-04906]\]. The advantage of point shear wave elastography is that it can be performed under B-mode ultrasound, so tumors and large vessels can be avoided. The disadvantages of point shear wave elastography are a small ROI and lack of real-time stiffness imaging. Point SWE has similar diagnostic performance as one-dimensional transient elastography and can be performed during the daily ultrasound examination.

### 2.1.4. Two-Dimensional Shear Wave Elastography {#sec2dot1dot4-ijms-21-04906}

Two-dimensional (2D) SWE is the most recently introduced technique. Two-dimensional SWE uses multiple ARFIs at multiple locations. In a meta-analysis including 13 sites with 1134 patients with HCV, HBV, or nonalcoholic fatty liver disease (NAFLD), the diagnostic performance of 2D SWE for differentiating significant fibrosis (F2), severe fibrosis (F3), and cirrhosis were shown in [Table 1](#ijms-21-04906-t001){ref-type="table"} \[[@B14-ijms-21-04906]\]. Two-dimensional elastography has a real-time color-coded map, and heterogeneity can also be evaluated along with the stiffness value.

2.2. Magnetic Resonance Imaging (MRI) Elastography {#sec2dot2-ijms-21-04906}
--------------------------------------------------

MRI elastography has the advantage of assessing the whole liver, compared to the limited assessment by US elastography or even liver biopsy. Continuous mechanical waves (60 Hz mechanical compressions) are produced from the active driver outside the examination room to the passive driver positioned on the patient's body over the liver, resulting in periodic liver tissue displacement \[[@B26-ijms-21-04906]\]. In a meta-analysis, including 12 studies with various etiologies \[[@B27-ijms-21-04906]\], the diagnostic performance of MRE is as demonstrated in [Table 1](#ijms-21-04906-t001){ref-type="table"}. It is essential to know that the measured parameters of liver stiffness are not equal between the different techniques \[[@B28-ijms-21-04906]\]. For instance, although transient elastography and MRE have different mechanisms and different thresholds for the diagnosis of cirrhosis, both measurements are expressed in kPa. Since measurement failure for obese patients is common in ultrasound-based elastography, MRI elastography could be especially useful in those obese nonalcoholic fatty liver disease (NAFLD) patients.

2.3. Noninvasive Biomarkers and Their Combinations {#sec2dot3-ijms-21-04906}
--------------------------------------------------

Liver function tests are routinely used for the management of all chronic liver diseases. AST, alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), total bilirubin, albumin, prothrombin time (PT), and platelet count are routinely checked in out-patient clinics. Noninvasive biomarkers can be applied together with the routine blood draw. The features and diagnostic performance of each test are shown in [Table 3](#ijms-21-04906-t003){ref-type="table"}.

### 2.3.1. FibroTest^®^ {#sec2dot3dot1-ijms-21-04906}

FibroTest^®^ (Biopredictive, Paris, France) (FT) is a biomarker of liver fibrosis that was initially reported and validated in patients with chronic HCV infection \[[@B29-ijms-21-04906]\]. This test includes α2-macroglobulin, haptoglobin, GGT, γ-globulin, total bilirubin, and apolipoprotein A1. In a meta-analysis including a total of 30 studies, the individual data were analyzed in 3282 patients and AUROCs are demonstrated in [Table 3](#ijms-21-04906-t003){ref-type="table"} \[[@B30-ijms-21-04906]\]. FT is a commercially available test and has good performance in the diagnosis of the liver fibrosis stage.

### 2.3.2. APRI {#sec2dot3dot2-ijms-21-04906}

AST to platelet ratio index (APRI) was calculated as (AST level /upper limit of normal \[ULN\])/platelet counts (10^9^/L) × 100 \[[@B36-ijms-21-04906]\]. The result can be obtained from a web-based calculator. In a meta-analysis, including 40 hepatitis C-related fibrosis studies and 16 hepatitis B-related fibrosis studies, the diagnostic performance was as shown in [Table 3](#ijms-21-04906-t003){ref-type="table"} \[[@B32-ijms-21-04906],[@B33-ijms-21-04906]\]. APRI is an index obtained from general blood tests and its diagnostic performance is comparable with other serum tests.

### 2.3.3. FIB-4 Index {#sec2dot3dot3-ijms-21-04906}

The FIB-4 index was first reported and proposed by the authors of the AIDS Pegasys Ribavirin International Coinfection Trial (APRICOT) as an index that could predict the fibrosis stage in patients coinfected with human immunodeficiency virus (HIV) and HCV \[[@B33-ijms-21-04906]\]. The index comprises age, AST, platelet count, and ALT and is calculated as (age \[years\] × AST \[U/L\])/(platelet counts \[10^9^/L\] × ALT^1/2^ \[U/L\]). In an original study and a meta-analysis including 22 HBV-related fibrosis studies, the diagnostic performance was as shown in [Table 3](#ijms-21-04906-t003){ref-type="table"} \[[@B34-ijms-21-04906]\]. In a multicenter study from Japan, the modified cutoff points were reported for different ages \[[@B37-ijms-21-04906]\]. Fibrosis progression of chronic HCV infection is slow and generally takes several decades to develop liver cirrhosis \[[@B38-ijms-21-04906]\]. Fibrosis progression rate in chronic HCV infection is known to depend on patients' characteristics at the onset of infection such as age, gender, alcohol consumption \[[@B39-ijms-21-04906],[@B40-ijms-21-04906],[@B41-ijms-21-04906]\]. Patients with rapid fibrosis progression would have died young, and those with slow progression would be able to live longer \[[@B42-ijms-21-04906]\]. Whether the fibrosis indices should include age probably depends on the disease etiology and epidemiology. The FIB-4 index is comprised of parameters readily available in daily clinical practice.

3. Molecular Mechanism of Fibrosis {#sec3-ijms-21-04906}
==================================

3.1. Mechanism of Fibrosis {#sec3dot1-ijms-21-04906}
--------------------------

The mechanism of liver fibrosis has been vigorously studied, and TGF-β1 activation, stellate cell activation and deposition of ECM, and imbalance of MMPs and TIMPs are thought to be of paramount importance in fibrogenesis. One of the pathological features of liver fibrosis is the increased expression of collagens, fibronectins, proteoglycans, structural glycoproteins, and hyaluronan \[[@B43-ijms-21-04906],[@B44-ijms-21-04906],[@B45-ijms-21-04906]\]. Fibronectin seems to play a key role in this process. On one hand, fibronectin seems to affect TGF-β release \[[@B46-ijms-21-04906]\], and on the other hand, its production is required for the accumulation of collagen and hence fibrosis development \[[@B47-ijms-21-04906],[@B48-ijms-21-04906]\]. Collagens are degraded by MMPs, which, together with their inhibitors, termed TIMPs, play a key role in fibrogenesis and fibrolysis \[[@B49-ijms-21-04906],[@B50-ijms-21-04906],[@B51-ijms-21-04906]\]. These enzymes can be noninvasive fibrosis markers as they are directly involved in liver fibrosis. The family of human MMPs comprises more than 24 members and can be divided into the subgroups collagenases, gelatinases, stromelysins, matrilysins, membrane-type MMPs, and others \[[@B45-ijms-21-04906],[@B52-ijms-21-04906]\]. Each MMP is described in the following sections based on the subgroup. Representative mechanism of MMPs and TIMPs in liver fibrosis is demonstrated in [Figure 2](#ijms-21-04906-f002){ref-type="fig"}. Summary of MMPs and TIMPs are shown in [Table 4](#ijms-21-04906-t004){ref-type="table"}.

### 3.1.1. Collagenase Subgroup {#sec3dot1dot1-ijms-21-04906}

MMP-1, MMP-8, MMP-13, and MMP-18 are classified in this group. These enzymes can cleave interstitial collagens I, II, and III. First MMP, MMP-1 was discovered by Dr. Gross in 1962 from tadpole tissue \[[@B53-ijms-21-04906]\]. During the metamorphosis, removal and remodeling of the tissue is precisely controlled by proteinases including MMP-1. MMP-1 plays an important role in the regression of liver fibrosis in rodents. MMP-1 degrades key collagens in hepatic fibrosis and is a promising marker for antifibrotic therapy. MMP-1 mRNA was elevated in the fibrotic and cirrhotic liver of chronic hepatitis C patients \[[@B54-ijms-21-04906]\]. Overexpression of MMP-1 induced by human adenovirus vector expressing MMP-1 (AdMMP-1) injection attenuated liver fibrosis and stimulated hepatocyte proliferation in a rat fibrosis model \[[@B54-ijms-21-04906]\]. The improvement after cholestatic liver injury correlated with MMP-8 activity \[[@B56-ijms-21-04906]\]. The overexpression of MMP-8 reduced fibrosis in rat fibrosis models \[[@B57-ijms-21-04906]\]. MMP-2, MMP-8, and MMP-9 were reported to be serum markers of disease severity in patients with alcoholic liver disease \[[@B58-ijms-21-04906]\]. A dermal wound healing model in MMP-13 knockout mice showed decreased myofibroblast proliferation and TGF-β1 level, which indicated that MMP-13 was involved in that TGF-β1 activation \[[@B59-ijms-21-04906]\]. MMP-13 is reported to be useful for predicting alcoholic liver cirrhosis; however, the MMP-1 levels are not significantly elevated in cirrhotic patients compared to controls \[[@B60-ijms-21-04906]\]. The collagenase group is capable of degrading the triple helix conformation of native collagens \[[@B102-ijms-21-04906]\].

### 3.1.2. Gelatinase Subgroup {#sec3dot1dot2-ijms-21-04906}

MMP-2 (gelatinase A) and MMP-9 (gelatinase B) are classified in this group. MMP-2 degrades type I, II, and III collagens \[[@B61-ijms-21-04906],[@B62-ijms-21-04906]\]. MMP-2 suppresses collagen I expression \[[@B63-ijms-21-04906]\], and the loss of MMP-2 aggravates fibrosis, suggesting that MMP-2 suppresses TIMP-1 upregulation during liver fibrosis \[[@B64-ijms-21-04906]\]. MMP-9 promotes apoptosis of HSCs \[[@B65-ijms-21-04906]\] and is expressed in HCC \[[@B66-ijms-21-04906],[@B67-ijms-21-04906]\]. In a murine model, MMP-9 was used as a therapeutic target for fulminant hepatic failure, and its inhibition led to prolonged survival by improving hepatic and brain injury at an early stage \[[@B68-ijms-21-04906]\]. The gelatinases subgroup has three repeats of a type II fibronectin domain inserted in the catalytic domain, which allows for the binding to and processing of denatured gelatin and collagens \[[@B103-ijms-21-04906]\].

### 3.1.3. Stromelysin Subgroup {#sec3dot1dot3-ijms-21-04906}

MMP-3 (stromelysin 1) and MMP-10 (stromelysin 2) are classified in this group. Both MMPs have a similar structure; however, MMP-3 has a higher proteolytic ability than MMP-10. MMP-3 activates several pro-MMPs, and its action on pro-MMP1 seems to be important for the production of fully active MMP-1 \[[@B69-ijms-21-04906]\]. The strong overall expression of MMP-3 and MMP-10 was found in HCCs, especially in the ECM adjacent to blood vessels \[[@B70-ijms-21-04906]\]. Compared with healthy controls, serum samples from patients with chronic diseases had a 50% reduction in serum MMP-3 levels, as measured by enzyme-linked immunosorbent assays \[[@B71-ijms-21-04906]\]. MMP-11 is called stromelysin 3, which plays a vital role during tumor migration, invasion, and metastasis \[[@B72-ijms-21-04906],[@B73-ijms-21-04906]\]. The association between five single nucleotide polymorphisms (SNPs) (rs738791, rs2267029, rs738792, rs28382575, and rs131451) of the MMP-11 gene and HCC development, along with other clinical outcomes such as development of moderate to severe liver failure and distant metastasis, were reported in 293 patients with HCC and in 586 cancer-free controls \[[@B74-ijms-21-04906]\]. The carriers of the mutant allele (CT+TT) of the rs738791 variant had a higher risk of HCC than wild-type (CC) carriers. The stromelysin group is capable of cleaving extracellular matrix proteins and its relationship with HCC is reported \[[@B74-ijms-21-04906]\].

### 3.1.4. Matrilysin Subgroup {#sec3dot1dot4-ijms-21-04906}

MMP-7 (matrilysin 1) and MMP-26 (matrilysin 2) are classified in this group \[[@B75-ijms-21-04906],[@B76-ijms-21-04906]\]. In addition to ECM degradation, MMP-7 processes cell surface molecules such as pro-α-defensin, Fas-ligand, pro-tumor necrosis factor (TNF)-α, and E-cadherin. The mRNA and protein level of MMP-7 is positively related to the progression of liver fibrosis in biliary atresia \[[@B76-ijms-21-04906]\]. MMP-7 is also reported to be involved in human cancer metastases \[[@B77-ijms-21-04906]\]. MMP-26 digests several ECM components and activates pro-MMP-9 by cleavage \[[@B79-ijms-21-04906]\]. The common structure of MMP consists of four domains: a signal peptide to direct secretion from the cell; a propeptide maintaining enzyme latency; a catalytic domain with a Zn-binding site; and a hemopexin-like domain at the C-terminal region \[[@B51-ijms-21-04906]\]. The common feature of the matrilysin group is that they all lack a hemopexin domain and are the smallest MMP in size.

### 3.1.5. Membrane-Type MMP Subgroup {#sec3dot1dot5-ijms-21-04906}

There are six membrane-type MMPs (MT-MMPs): four are type I transmembrane proteins (MT1-MMP \[MMP-14\], MT2- MMP \[MMP-15\], MT3-MMP \[MMP-16\], and MT5-MMP \[MMP-24\]), and two are glycosylphosphatidylinositol (GPI)-anchored proteins (MT4-MMP \[MMP-17\] and MT5-MMP \[MMP-25\]). Most MMPs are secreted in the extracellular environment, however, MT-MMPs are secreted in the plasma membrane of the producing cells, suggesting MT-MMP are essential in pericellular ECM degradation. The first MT-MMP, MT1-MMP was discovered and characterized as a cell surface proMMP-2 activator. MT1-MMP has a collagenolytic activity on type I, II, and III collagens and associated with cell invasions in malignant tumors \[[@B80-ijms-21-04906]\]. MT1-MMP was reported to be overexpressed in highly invasive HCC with its invading border of the tumor \[[@B81-ijms-21-04906]\]. MT1-MMPdeficient mice had severe skeletal defects possibly due to a decreased vascular invasion of calcified cartilage and it also seemed to play an important role in angiogenesis \[[@B82-ijms-21-04906]\]. HBV X-interacting protein (HBXIP) promotes HCC cell migration and invasion through MT2-MMP. The silencing of MT2-MMP partly decreases the cell migration and invasion promoted by HBXIP overexpression \[[@B83-ijms-21-04906]\]. MT3-MMP also promotes cell invasion and metastases \[[@B84-ijms-21-04906]\]. MT4-MMP is reported to be expressed on the cell surface of human breast cancer cells and promotes primary tumor growth and lung metastasis \[[@B85-ijms-21-04906]\]. MT5-MMP is brain-specific and is mainly expressed in the cerebellum and associated with neuronal development \[[@B86-ijms-21-04906]\]. MT6-MMP is expressed predominantly in peripheral blood leukocytes, anaplastic astrocytoma, colon carcinoma cells, and glioblastoma, but not in normal colon, and meningioma \[[@B87-ijms-21-04906],[@B88-ijms-21-04906]\].

### 3.1.6. Other MMPs Subgroup {#sec3dot1dot6-ijms-21-04906}

Six MMPs are not classified in the above-mentioned categories. MMP-12 (metalloelastase) mainly expressed in macrophages digests elastin and is reported to be associated with pulmonary fibrosis and chronic obstructive pulmonary disease \[[@B89-ijms-21-04906],[@B90-ijms-21-04906]\]. MMP-19 was identified from a human liver cDNA library and from a synovial membrane of a patient with rheumatoid arthritis \[[@B91-ijms-21-04906],[@B92-ijms-21-04906]\]. MMP-19 is reported to play an important role in the development of liver injury and subsequent fibrosis through influencing TGF-β1 and the insulin-like growth factor-1 (IGF-1) signaling pathway \[[@B93-ijms-21-04906]\].

MMP-20 (enamelysin), which digests amelogenin, is primarily located within newly formed tooth enamel \[[@B94-ijms-21-04906]\]. MMP-22 was first cloned from chicken fibroblasts, and the function of this enzyme is not known \[[@B95-ijms-21-04906]\]. MMP-23, also called cysteine array MMP, is mainly expressed in reproductive tissues \[[@B96-ijms-21-04906],[@B97-ijms-21-04906]\]. The latest addition to the MMP family is epilysin (MMP-28), which is mainly expressed in normal tissues, such as testis, intestine, lung, and skin. In addition, its expression patterns in injured skin suggest that MMP-28 functions in tissue hemostasis and wound repair \[[@B99-ijms-21-04906],[@B100-ijms-21-04906],[@B101-ijms-21-04906]\]. MMP-28 promotes the epithelial to mesenchymal transition (EMT), migration, and invasion of HCC cells \[[@B101-ijms-21-04906]\].

### 3.1.7. TIMPs {#sec3dot1dot7-ijms-21-04906}

Four TIMPs (TIMP-1, TIMP-2, TIMP-3, and TIMP-4) are known to be associated with liver fibrosis. All MMPs can be inhibited by at least one of the TIMPs. In patients with HCV, TIMP-1 serum protein and mRNA levels are positively correlated with the staging of liver fibrosis \[[@B104-ijms-21-04906],[@B105-ijms-21-04906]\]. In situ hybridization and immunoelectron microscopy revealed TIMP-1 was localized in fibrosis septa and was possibly produced from activated HSCs \[[@B105-ijms-21-04906]\]. Since TIMP-1 is also significantly associated with fibrogenesis in the lungs \[[@B106-ijms-21-04906],[@B107-ijms-21-04906]\], kidneys \[[@B108-ijms-21-04906],[@B109-ijms-21-04906]\], and pancreas \[[@B110-ijms-21-04906],[@B111-ijms-21-04906]\], TIMP-1 seems to play a central role in tissue fibrosis. A summary of four TIMPs are shown in [Table 5](#ijms-21-04906-t005){ref-type="table"}.

In patients infected with HCV, elevated serum protein levels and mRNA expression of TIMP-2 were reported \[[@B112-ijms-21-04906],[@B113-ijms-21-04906]\]. In rat bile duct ligation model, the mRNA expression level of TIMP-2 was elevated after 10 days and showed no further change until 30 days \[[@B114-ijms-21-04906]\]. A zymography study using tissue extracts revealed that TIMP-2 was necessary for activating latent pro-MMP-2 \[[@B115-ijms-21-04906]\]. TIMP-2 also has an inhibitory function against MT1-MMP, as demonstrated in a *Timp-2* deficient mouse model \[[@B116-ijms-21-04906]\].

TIMP-3 inhibits a disintegrin and metalloproteinase 17 (ADAM17) and its essential role in the liver was confirmed in a *Timp-3* deficient mouse model. Timp-3 deficient mice suffered necrosis, apoptosis, and morbidity after partial hepatectomy, due to the inability to downregulate hepatic TNF levels \[[@B117-ijms-21-04906]\].

Mice lacking TIMP-4 had greater activity of MT1-MMP with increased inflammation, indicating that TIMP-4 regulates ECM deposition through MT1-MMP inhibition \[[@B118-ijms-21-04906]\].

As shown above, TIMPs are not only the inhibitors of MMP; they have other independent biological functions, too.

### 3.1.8. Fibronectin Isoforms {#sec3dot1dot8-ijms-21-04906}

Fibrosis results from accumulation of fibronectin leading to collagen accumulation \[[@B47-ijms-21-04906]\]. Most of the circulating fibronectin is called plasma fibronectin and lacks three characteristics that make fibronectin accumulate in the matrix. These are the presence of an EDA domain, and EDB domain or a glycosylation site leading to fibronectin being called oncofetal fibronectin. Since these isoforms are produced by the hepatic stellate cells that are responsible for matrix production \[[@B119-ijms-21-04906]\], these isoforms were detected in patients with liver disease \[[@B120-ijms-21-04906]\] and therefore evaluated in relationship to fibrosis and were found to predict the degree of fibrosis in chronic hepatitis C \[[@B121-ijms-21-04906]\]. An increase in the isoform EDA over 1.32 and the isoform oFN over 3.26 in combination predicted significant fibrosis with a specificity \>99%, while values below 0.78 for EDA and below 1.88 for oFN excluded significant fibrosis with a specificity of 94%. These encouraging results are probably due to the fact that the two molecules measured represent substances that directly accumulate in fibrotic tissue.

### 3.1.9. Mac-2 Binding Protein Glycan Isomer (M2BPGi) {#sec3dot1dot9-ijms-21-04906}

Fibrosis-related glycol alterations of hyperglycosylated Mac-2 binding protein (M2BP) were identified by glycan-based immunoassay and fibrosis-specific modified M2BP was termed Mac-2 binding protein glycosylation isomer (M2BPGi) \[[@B122-ijms-21-04906],[@B123-ijms-21-04906]\]. M2BPGi was detected using a lectin called *Wisteria floribunda agglutinin* that binds specifically to M2BPGi \[[@B124-ijms-21-04906]\]. In a meta-analysis, including 21 studies, the diagnostic performance is as shown in [Table 3](#ijms-21-04906-t003){ref-type="table"} \[[@B35-ijms-21-04906]\]. Cutoff values for fibrosis stages differ among HBV- and HCV-related liver disease \[[@B125-ijms-21-04906]\]. The difference might reflect the different mechanisms of liver fibrogenesis and should be evaluated in future studies.

4. Conclusions {#sec4-ijms-21-04906}
==============

Accurate diagnosis of liver fibrosis is essential in the management of chronic liver disease, as the fibrosis stage is regarded as a surrogate marker for evaluating the severity of the disease. US and MR elastography have become prominent as noninvasive methods for quantifying hepatic fibrosis, and they are now widely applied in clinical practice. The limitations of elastography are mainly technical challenges: the need for better-quality measurement in obese patients, threshold standardization, and cost reduction. Fibrosis seems to develop and progress as a consequence of alterations in matrix production and/or degradation, accompanied by increased matrix production. Understanding the factors that lead to increased matrix production or decreased matrix degradation will lead to new fibrosis marker development and eventually to a discovery of antifibrotic reagents. Further studies are required to establish more accurate fibrosis markers based on molecular research.
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![Molecular mechanism and diagnosis of development of liver fibrosis. Hepatocellular injury causes TGF-β1 activation. In turn, TGF-β1 activates hepatic stellate cell and increases ECM production, causing liver fibrosis and cirrhosis. The development is depending on the balance between fibrolysis and fibrogenesis. ECM turnover is controlled by MMPs and TIMPs. Liver fibrosis can be assessed by elastography and serum markers such as aspartate aminotransferase (AST) to platelet ratio index (APRI), FIB-4, and Mac-2 binding protein glycosylation isomer (M2BPGi). US, ultrasound; MRI, magnetic resonance imaging; HCV, hepatitis C virus; HBV, hepatitis B virus; ALD, alcoholic liver disease; NASH, nonalcoholic steatohepatitis; APRI, aspartate aminotransferase to platelet ratio index; M2BPGi, Mac-2 binding protein glycosylation isomer; MMPs, matrix metalloproteinase; TIMPs, tissue inhibitors of metalloproteinases; TGF-β1, transforming growth factor β1.](ijms-21-04906-g001){#ijms-21-04906-f001}

![Representative mechanism of matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) in liver fibrosis. Red arrows indicate activation, blue arrows indicate inhibition. TGF-β1, transforming growth factor β1. TIMP-1 is produced by activated stellate cell, hepatocyte, and Kupffer cell. TIMP-1 is regulated by TGF-β1 and inhibits collagenase (MMP-1, 8, 13) and apoptosis of hepatic stellate cell, causing liver fibrosis and cirrhosis. TIMP-2 is produced by activated stellate cell and Kupffer cell. TIMP-2 inhibits MMP-2 and also activates pro-MMP-2, causing degradation of normal liver matrix.](ijms-21-04906-g002){#ijms-21-04906-f002}
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###### 

Summary of diagnostic performances of elastography reported in meta-analyses.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------
  Elastography                                          Etiology                            F2      F3     F4                         Reference
  ----------------------------------------------------- -------------------- -------------- ------- ------ -------------------------- --------------------------
  One-dimensional Ultrasound (Transient elastography)   Various etiologies   Cutoff (kPa)   7.65    N/A    13.01                      \[[@B10-ijms-21-04906]\]

  Sensitivity                                           N/A                  N/A            N/A                                       

  Specificity                                           N/A                  N/A            N/A                                       

  AUROC                                                 0.84                 0.89           0.94                                      

  HBV                                                   Cutoff (kPa)         7.9            8.8     11.7   \[[@B11-ijms-21-04906]\]   

  Sensitivity                                           74.3                 74.0           84.6                                      

  Specificity                                           78.3                 63.8           81.5                                      

  AUROC                                                 0.859                0.887          0.929                                     

  Point shear wave\                                     Various etiologies   Cutoff (m/s)   1.31    N/A    1.80                       \[[@B12-ijms-21-04906]\]
  Ultrasound                                                                                                                          

  Sensitivity                                           74                   N/A            87                                        

  Specificity                                           83                   N/A            87                                        

  AUROC                                                 0.85                 N/A            0.93                                      

  Nonviral                                              Cutoff (m/s)         N/A            N/A     N/A    \[[@B13-ijms-21-04906]\]   

  Sensitivity                                           79                   92             89                                        

  Specificity                                           81                   85             89                                        

  AUROC                                                 0.87                 0.94                                                     

  Two dimensional\                                      HCV                  Cutoff (kPa)   7.1     9.2    13.0                       \[[@B14-ijms-21-04906]\]
  Ultrasound                                                                                                                          

  Sensitivity                                           94.7                 90.3           85.8                                      

  Specificity                                           52.0                 76.8           87.8                                      

  AUROC                                                 0.863                0.915          0.929                                     

  HBV                                                   Cutoff (kPa)         7.1            8.1     11.5                              

  Sensitivity                                           87.6                 94.9           79.9                                      

  Specificity                                           73.6                 73.1           93.3                                      

  AUROC                                                 0.906                0.931          0.955                                     

  NAFLD                                                 Cutoff (kPa)         7.1            9.2     13.0                              

  Sensitivity                                           93.8                 93.1           75.3                                      

  Specificity                                           52.0                 80.9           87.8                                      

  AUROC                                                 0.855                0.928          0.917                                     

  Others                                                Cutoff (kPa)         7.1            9.2     13.0                              

  Sensitivity                                           94.8                 95.1           79.4                                      

  Specificity                                           39.9                 86.6           83.6                                      

  AUROC                                                 N/A                  N/A            N/A                                       

  MRI elastography                                      Various etiologies   Cutoff (kPa)   3.66    4.11   4.71                       \[[@B15-ijms-21-04906]\]

  Sensitivity                                           79                   85             91                                        

  Specificity                                           81                   85             81                                        

  AUROC                                                 0.88                 0.93           0.92                                      
  --------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: MRI, magnetic resonance imaging; HBV, hepatitis B virus; HCV, hepatitis C virus; NAFLD, nonalcoholic fatty liver disease; AUROC, area under the receiver operating characteristic; F, fibrosis stage; N/A, not available.
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###### 

Characteristics of elastography.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Elastography       Technique                       Advantages                                                                                Disadvantages                                                                  References
  ------------------ ------------------------------- ----------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  US elastography    Static strain imaging           Real-time imaging with elastogram which can distinguish a tumor from background tissue.   Variability due to inconsistent compression (heartbeat). Semi-quantification   \[[@B16-ijms-21-04906],[@B17-ijms-21-04906]\]

                     1D transient elastography       The most widely used and validated.                                                       Needs special equipment.\                                                      \[[@B10-ijms-21-04906],[@B11-ijms-21-04906],[@B18-ijms-21-04906],[@B19-ijms-21-04906],[@B20-ijms-21-04906],[@B21-ijms-21-04906],[@B22-ijms-21-04906],[@B23-ijms-21-04906],[@B24-ijms-21-04906],[@B25-ijms-21-04906]\]
                                                                                                                                               Lacking B-mode                                                                 

                     Point shear wave elastography   Controllable ROI                                                                          Small ROI. Needs high-end US apparatus                                         \[[@B12-ijms-21-04906],[@B13-ijms-21-04906]\]

                     2D shear wave elastography      Controllable ROI.\                                                                        Needs high-end US apparatus                                                    \[[@B14-ijms-21-04906]\]
                                                     Real-time imaging                                                                                                                                                        

  MRI elastography                                   Assessment of whole liver                                                                 Needs special equipment\                                                       \[[@B26-ijms-21-04906],[@B27-ijms-21-04906],[@B28-ijms-21-04906]\]
                                                                                                                                               Not indicated to patients with claustrophobia                                  
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviation: US, ultrasound; B-mode, brightness-mode; ROI, region of interest; 1D, one dimensional; 2D, two dimensional.
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###### 

Serum tests and their diagnostic performances.

                Factors                                                                                  Etiology                        F2           F3                         F4           Reference
  ------------- ---------------------------------------------------------------------------------------- ------------------ ------------ ------------ -------------------------- ------------ -----------------------------------------
  FibroTest     α2-macroglobulin, haptoglobin, GGT, γ-globulin, total bilirubin, and apolipoprotein A1   HCV                AUROC        0.66         0.66                       0.66         \[[@B30-ijms-21-04906]\]
  HBV           AUROC                                                                                    0.63               0.78         0.54                                                 
  ALD           AUROC                                                                                    0.65               0.66         0.82                                                 
  NAFLD         AUROC                                                                                    0.69               0.69         0.71                                                 
  APRI          AST, platelet count                                                                      HCV                Cutoff       0.7          1.0                        2.0          \[[@B31-ijms-21-04906]\]
  Sensitivity   77                                                                                       61                 46                                                                
  Specificity   72                                                                                       64                 91                                                                
  AUROC         0.77                                                                                     0.80               0.83                                                              
  HBV           Cutoff                                                                                   0.5                1.0          1.5          \[[@B32-ijms-21-04906]\]                
  Sensitivity   70                                                                                       50                 36.9                                                              
  Specificity   60                                                                                       83                 92.5                                                              
  AUROC         0.72                                                                                     0.76               0.72                                                              
  FIB-4 Index   Age, AST, ALT, platelet count                                                            HCV                Cutoff                    3.25                                    \[[@B33-ijms-21-04906]\] (single study)
  Sensitivity                                                                                            23                                                                                   
  Specificity                                                                                            97                                                                                   
  AUROC                                                                                                  0.737                                                                                
  HBV           Cutoff                                                                                   0.8--1.085         1.45--1.65   2.9--3.6     \[[@B34-ijms-21-04906]\]                
  Sensitivity   73                                                                                       68                 42                                                                
  Specificity   62                                                                                       75                 96                                                                
  AUROC         0.73                                                                                     0.77               0.96                                                              
  M2BPGi                                                                                                 Various etiology   Cutoff       0.90--1.42   0.94--3.70                 1.26--4.62   \[[@B35-ijms-21-04906]\]
  Sensitivity   69                                                                                       76                 82                                                                
  Specificity   78                                                                                       76                 84                                                                
  AUROC         N/A                                                                                      N/A                N/A                                                               

Abbreviations: Ref, reference; GGT, gamma-glutamyl transferase; HCV, hepatitis C virus; HBV, hepatitis B virus; ALD, alcoholic liver disease; NAFLD, nonalcoholic fatty liver disease; AUROC, area under the receiver characteristic; F, fibrosis stage; APRI, aspartate transaminase to platelet ratio index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; M2BPGi, Mac-2 binding protein glycosylation isomer; N/A, not available.
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###### 

Summary of matrix metalloproteinases (MMPs).

  MMP Classification   Type      Aliases                                           Pathology                                                             References
  -------------------- --------- ------------------------------------------------- --------------------------------------------------------------------- -------------------------------------------------------------------------------------------
  Collagenases         MMP-1     Interstitial collagenase                          ECM degradation                                                       \[[@B53-ijms-21-04906],[@B54-ijms-21-04906],[@B55-ijms-21-04906]\]
                       MMP-8     Neutrophil collagenase                            Fibrosis attenuation                                                  \[[@B56-ijms-21-04906],[@B57-ijms-21-04906],[@B58-ijms-21-04906]\]
                       MMP-13    Collagenase 3                                     Promote TGF-β1 activation                                             \[[@B59-ijms-21-04906],[@B60-ijms-21-04906]\]
  Gelatinases          MMP-2     Gelatinase A                                      Suppress collagen I expression                                        \[[@B61-ijms-21-04906],[@B62-ijms-21-04906],[@B63-ijms-21-04906],[@B64-ijms-21-04906]\]
                       MMP-9     Gelatinase B                                      Promote apoptosis of HSCs                                             \[[@B65-ijms-21-04906],[@B66-ijms-21-04906],[@B67-ijms-21-04906],[@B68-ijms-21-04906]\]
  Stromelysins         MMP-3     Stromelysin-1                                     ECM degradation. Activate pro-MMPs                                    \[[@B69-ijms-21-04906],[@B70-ijms-21-04906],[@B71-ijms-21-04906]\]
                       MMP-10    Stromelysin-2, Transin-2                          Found in HCC                                                          \[[@B72-ijms-21-04906],[@B73-ijms-21-04906]\]
                       MMP-11    Stomelysin-3                                      Tumor migration, invasion, metastasis                                 \[[@B74-ijms-21-04906]\]
  Matrilysins          MMP-7     Matrilysin-1, Pump-1, Uterine metalloproteinase   Activated in biliary atresia related liver fibrosis                   \[[@B75-ijms-21-04906],[@B76-ijms-21-04906],[@B77-ijms-21-04906]\]
                       MMP-26    Matrilysin-2, Endometase                          ECM degradation and activates MMP-9                                   \[[@B75-ijms-21-04906],[@B78-ijms-21-04906],[@B79-ijms-21-04906]\]
  Membranous Type      MMP-14    MT1-MMP                                           Angiogenesis and activates MMP-2                                      \[[@B80-ijms-21-04906],[@B81-ijms-21-04906],[@B82-ijms-21-04906]\]
  MMP-15               MT2-MMP   Cell migration and invasion                       \[[@B83-ijms-21-04906]\]                                              
                       MMP-16    MT3-MMP                                           Cell invasion and metastases                                          \[[@B84-ijms-21-04906]\]
                       MMP-17    MT4-MMP                                           Expressed in breast cancer cells                                      \[[@B85-ijms-21-04906]\]
                       MMP-24    MT5-MMP                                           Brain specific                                                        \[[@B86-ijms-21-04906]\]
                       MMP-25    MT6-MMP                                           Expressed in peripheral blood leukocytes                              \[[@B87-ijms-21-04906],[@B88-ijms-21-04906]\]
  Others               MMP-12    Macrophage elastase                               Macrophage migration                                                  \[[@B89-ijms-21-04906],[@B90-ijms-21-04906]\]
                       MMP-19    RASI-1                                            Destruction and development of hepatic basement membrane              \[[@B91-ijms-21-04906],[@B92-ijms-21-04906],[@B93-ijms-21-04906]\]
                       MMP-20    Enamelysin                                        Degrades amelogenin                                                   \[[@B94-ijms-21-04906]\]
                       MMP-22    N/A                                               Cloned from chicken fibroblast                                        \[[@B95-ijms-21-04906]\]
                       MMP-23    Femalysin                                         Expressed in reproductive tissues                                     \[[@B96-ijms-21-04906],[@B97-ijms-21-04906]\]
                       MMP-28    Epilysin                                          Degrades casein. Promotes EMT, migration and invasion of HCC cells.   \[[@B98-ijms-21-04906],[@B99-ijms-21-04906],[@B100-ijms-21-04906],[@B101-ijms-21-04906]\]

Abbreviation: MMP, matrix metalloproteinase; MT, membrane type; ECM, extracellular matrix; TGF-β1, transforming growth factor-beta1; HSC, hepatic stellate cell; HCC, hepatocellular carcinoma; EMT, epithelial to mesenchymal transition; N/A, not available.
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###### 

Summary of tissue inhibitors of metalloproteinase.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  TIMP Classification   Pathology                                                 References
  --------------------- --------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  TIMP1                 Inhibition of collagenase\                                \[[@B104-ijms-21-04906],[@B105-ijms-21-04906],[@B106-ijms-21-04906],[@B107-ijms-21-04906],[@B108-ijms-21-04906],[@B109-ijms-21-04906],[@B110-ijms-21-04906],[@B111-ijms-21-04906]\]
                        Inhibition of activation of pro-MMPs\                     
                        Inhibition of programmed cell death of HSCs               

  TIMP2                 Inhibition of MT1-MMP, MMP-2\                             \[[@B112-ijms-21-04906],[@B113-ijms-21-04906],[@B114-ijms-21-04906],[@B115-ijms-21-04906],[@B116-ijms-21-04906]\]
                        Activation of pro-MMP2                                    

  TIMP3                 Promotion of apoptosis\                                   \[[@B117-ijms-21-04906]\]
                        Regulation of inflammation through inhibition of ADAM17   

  TIMP4                 Inhibition of MT1-MMP                                     \[[@B118-ijms-21-04906]\]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviation: MMP, matrix metalloproteinase; HSC, hepatic stellate cell; MT. membrane type; ADAM17, a disintegrin and metalloproteinase 17.
